363 related articles for article (PubMed ID: 15613479)
21. Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection.
Grooms TN; Vuong HR; Tyo KM; Malik DA; Sims LB; Whittington CP; Palmer KE; Matoba N; Steinbach-Rankins JM
Antimicrob Agents Chemother; 2016 Nov; 60(11):6518-6531. PubMed ID: 27550363
[TBL] [Abstract][Full Text] [Related]
22. Algal lectins as potential HIV microbicide candidates.
Huskens D; Schols D
Mar Drugs; 2012 Jul; 10(7):1476-1497. PubMed ID: 22851920
[TBL] [Abstract][Full Text] [Related]
23. Rice endosperm is cost-effective for the production of recombinant griffithsin with potent activity against HIV.
Vamvaka E; Arcalis E; Ramessar K; Evans A; O'Keefe BR; Shattock RJ; Medina V; Stöger E; Christou P; Capell T
Plant Biotechnol J; 2016 Jun; 14(6):1427-37. PubMed ID: 26800650
[TBL] [Abstract][Full Text] [Related]
24. Griffithsin has antiviral activity against hepatitis C virus.
Meuleman P; Albecka A; Belouzard S; Vercauteren K; Verhoye L; Wychowski C; Leroux-Roels G; Palmer KE; Dubuisson J
Antimicrob Agents Chemother; 2011 Nov; 55(11):5159-67. PubMed ID: 21896910
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of transmitted and founder human immunodeficiency virus type 1 envelopes to carbohydrate-binding agents griffithsin, cyanovirin-N and Galanthus nivalis agglutinin.
Hu B; Du T; Li C; Luo S; Liu Y; Huang X; Hu Q
J Gen Virol; 2015 Dec; 96(12):3660-3666. PubMed ID: 26407826
[TBL] [Abstract][Full Text] [Related]
26. Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity.
Moulaei T; Shenoy SR; Giomarelli B; Thomas C; McMahon JB; Dauter Z; O'Keefe BR; Wlodawer A
Structure; 2010 Sep; 18(9):1104-15. PubMed ID: 20826337
[TBL] [Abstract][Full Text] [Related]
27. Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate.
Kouokam JC; Huskens D; Schols D; Johannemann A; Riedell SK; Walter W; Walker JM; Matoba N; O'Keefe BR; Palmer KE
PLoS One; 2011; 6(8):e22635. PubMed ID: 21829638
[TBL] [Abstract][Full Text] [Related]
28. Isolation and characterization of adociavirin, a novel HIV-inhibitory protein from the sponge Adocia sp.
O'Keefe BR; Erim T; Beutler JA; Cardellina JH; Gulakowski RJ; Krepps BL; McMahon JB; Sowder RC; Johnson DG; Buckheit RW; Halliday S; Boyd MR
FEBS Lett; 1998 Jul; 431(1):85-90. PubMed ID: 9684871
[TBL] [Abstract][Full Text] [Related]
29. Preformulation Characterization of Griffithsin, a Biopharmaceutical Candidate for HIV Prevention.
Kramzer LF; Hamorsky KT; Graebing PW; Wang L; Fuqua JL; Matoba N; Lasnik AB; Moncla BJ; Zhang J; Palmer KE; Rohan LC
AAPS PharmSciTech; 2021 Feb; 22(3):83. PubMed ID: 33625602
[TBL] [Abstract][Full Text] [Related]
30. In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection.
Minooei F; Fried JR; Fuqua JL; Palmer KE; Steinbach-Rankins JM
Int J Nanomedicine; 2021; 16():1189-1206. PubMed ID: 33623382
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN.
Alexandre KB; Moore PL; Nonyane M; Gray ES; Ranchobe N; Chakauya E; McMahon JB; O'Keefe BR; Chikwamba R; Morris L
Virology; 2013 Nov; 446(1-2):66-76. PubMed ID: 24074568
[TBL] [Abstract][Full Text] [Related]
32. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models.
Barton C; Kouokam JC; Lasnik AB; Foreman O; Cambon A; Brock G; Montefiori DC; Vojdani F; McCormick AA; O'Keefe BR; Palmer KE
Antimicrob Agents Chemother; 2014; 58(1):120-7. PubMed ID: 24145548
[TBL] [Abstract][Full Text] [Related]
33. A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium.
Bokesch HR; O'Keefe BR; McKee TC; Pannell LK; Patterson GM; Gardella RS; Sowder RC; Turpin J; Watson K; Buckheit RW; Boyd MR
Biochemistry; 2003 Mar; 42(9):2578-84. PubMed ID: 12614152
[TBL] [Abstract][Full Text] [Related]
34. Griffithsin, a Highly Potent Broad-Spectrum Antiviral Lectin from Red Algae: From Discovery to Clinical Application.
Lee C
Mar Drugs; 2019 Oct; 17(10):. PubMed ID: 31590428
[No Abstract] [Full Text] [Related]
35. Differences in the mannose oligomer specificities of the closely related lectins from Galanthus nivalis and Zea mays strongly determine their eventual anti-HIV activity.
Hoorelbeke B; Van Damme EJ; Rougé P; Schols D; Van Laethem K; Fouquaert E; Balzarini J
Retrovirology; 2011 Feb; 8(1):10. PubMed ID: 21314946
[TBL] [Abstract][Full Text] [Related]
36. Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding.
Ziółkowska NE; O'Keefe BR; Mori T; Zhu C; Giomarelli B; Vojdani F; Palmer KE; McMahon JB; Wlodawer A
Structure; 2006 Jul; 14(7):1127-35. PubMed ID: 16843894
[TBL] [Abstract][Full Text] [Related]
37. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope.
Hoorelbeke B; Huskens D; Férir G; François KO; Takahashi A; Van Laethem K; Schols D; Tanaka H; Balzarini J
Antimicrob Agents Chemother; 2010 Aug; 54(8):3287-301. PubMed ID: 20498311
[TBL] [Abstract][Full Text] [Related]
38. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
[TBL] [Abstract][Full Text] [Related]
39. High-Mannose Specific Lectin and Its Recombinants from a Carrageenophyta Kappaphycus alvarezii Represent a Potent Anti-HIV Activity Through High-Affinity Binding to the Viral Envelope Glycoprotein gp120.
Hirayama M; Shibata H; Imamura K; Sakaguchi T; Hori K
Mar Biotechnol (NY); 2016 Feb; 18(1):144-60. PubMed ID: 26593063
[TBL] [Abstract][Full Text] [Related]
40. Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus.
Levendosky K; Mizenina O; Martinelli E; Jean-Pierre N; Kizima L; Rodriguez A; Kleinbeck K; Bonnaire T; Robbiani M; Zydowsky TM; O'Keefe BR; Fernández-Romero JA
Antimicrob Agents Chemother; 2015 Dec; 59(12):7290-8. PubMed ID: 26369967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
